Literature DB >> 25170316

Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.

Alison M Pack.   

Abstract

Entities:  

Year:  2014        PMID： 25170316      PMCID： PMC4120388          DOI： 10.5698/1535-7597-14.4.196

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  11 in total

1.  Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.

Authors:  Wim Van Paesschen; Edouard Hirsch; Martin Johnson; Ursula Falter; Philipp von Rosenstiel
Journal:  Epilepsia       Date:  2012-07-19       Impact factor: 5.864

2.  Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

Authors:  Patrick Kwan; Eugen Trinka; Wim Van Paesschen; Ivan Rektor; Martin E Johnson; Sarah Lu
Journal:  Epilepsia       Date:  2013-10-03       Impact factor: 5.864

3.  Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.

Authors:  J A French; C Costantini; A Brodsky; P von Rosenstiel
Journal:  Neurology       Date:  2010-06-30       Impact factor: 9.910

4.  Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

Authors:  Michel Gillard; Bruno Fuks; Karine Leclercq; Alain Matagne
Journal:  Eur J Pharmacol       Date:  2011-05-08       Impact factor: 4.432

5.  Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).

Authors:  K M Crowder; J M Gunther; T A Jones; B D Hale; H Z Zhang; M R Peterson; R H Scheller; C Chavkin; S M Bajjalieh
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

Authors:  Philippe Ryvlin; Konrad J Werhahn; Barbara Blaszczyk; Martin E Johnson; Sarah Lu
Journal:  Epilepsia       Date:  2013-10-28       Impact factor: 5.864

7.  SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.

Authors:  Rafal M Kaminski; Alain Matagne; Karine Leclercq; Michel Gillard; Philippe Michel; Benoit Kenda; Patrice Talaga; Henrik Klitgaard
Journal:  Neuropharmacology       Date:  2007-12-08       Impact factor: 5.250

8.  Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

Authors:  A Matagne; D-G Margineanu; B Kenda; P Michel; H Klitgaard
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

9.  Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.

Authors:  Erwin A van Vliet; Eleonora Aronica; Sandra Redeker; Karin Boer; Jan A Gorter
Journal:  Epilepsia       Date:  2008-08-19       Impact factor: 5.864

10.  Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.

Authors:  Cristina Zona; Massimo Pieri; Irene Carunchio; Livia Curcio; Henrik Klitgaard; Doru Georg Margineanu
Journal:  Epilepsy Res       Date:  2009-11-13       Impact factor: 3.045
View more
  4 in total

Review 1.  Brivaracetam: First Global Approval.

Authors:  Anthony Markham
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 2.  Brivaracetam add-on therapy for drug-resistant epilepsy.

Authors:  Rebecca Bresnahan; Mariangela Panebianco; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2022-03-14

3.  Brivaracetam add-on therapy for drug-resistant epilepsy.

Authors:  Rebecca Bresnahan; Mariangela Panebianco; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28

4.  Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy.

Authors:  Ersilia Savastano; Patrizia Pulitano; Maria Teresa Faedda; Leonardo Davì; Nicola Vanacore; Oriano Mecarelli
Journal:  Cureus       Date:  2021-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.